Bennett, M.I., Johnson, M.I., Brown, S.R., Radford, H., Brown, J.M., & Searle, R.D. (2010). Feasibility study of transcutaneous electrical nerve stimulation (TENS) for cancer bone pain. Journal of Pain, 11, 351–359.
To determine the feasibility of conducting a larger phase III trial to investigate the effectiveness of TENS for control of cancer-related bone pain
Patients were randomized to receive either active TENS at the first application and placebo TENS at the second application, or vice versa. Researchers responsible for outcome assessments were blinded to patient group. Placebo TENS was delivered using devices that were identical in appearance but delivered no current output. Patients were informed that sometimes they would feel a tingling sensation and sometimes they might not feel this. Patients were instructed not to tell the research observer any sensations they were feeling. Pain intensity measures were obtained at baseline, then repeated after 30 and 60 minutes of TENS application. Patients returned for the second TENS application two to seven days later and experienced an identical procedure. TENS application was given using a single channel device, and placement was based on recommendations for conventional TENS of the International Association for the Study of Pain. Pain was assessed at rest and on a patient-specified movement. Patients continued their current pain medication regimen.
A randomized, controlled, double-blind, crossover design was used.
The mean pain change in pain intensity score for active TENS was –0.84 compared with placebo TENS of –2.16. The mean change with movement was –2.32 for active TENS compared with placebo change of –2.0. at one hour. The mean pain relief on movement was higher with active TENS. The difference in proportion of patients who reported good or very good pain relief on movement with active TENS by verbal ratings was 36.8% (95% CI 7.5–66.2%). There were no clear patient preferences between active and placebo TENS. Three patients experienced adverse events, increased pain with TENS application, that were deemed likely to be or definitely related to TENS use.
TENS has the potential to provide improved pain relief on movement in patients with bone pain.
The study had a small sample, with less than 30 patients.
The purpose of this study was to determine feasibility and use findings to plan for a phase III study, rather than to determine intervention effect. Findings suggest that TENS may be more effective in pain relief on movement than for pain relief at rest for bone pain. Findings also showed an effect on the measure of pain relief, but not on the measure of pain intensity. This suggests that pain relief measurement may be more useful in clinical trials than just measurement of pain severity at given points in time.
Bennett, M.I., Bagnall, A.M., & Jose Closs, S. (2009). How effective are patient-based educational interventions in the management of cancer pain? Systematic review and meta-analysis. Pain, 143(3), 192–199.
To quantify and compare the benefits of various patient-based educational interventions for cancer pain management; to improve understanding of the relationship between education and improved pain outcomes
The search retrieved 61 studies. Authors chose 21 studies for analysis. Twelve studies included pain-outcome data suitable for meta-analysis. Authors used the Cochrane Collaboration recommendations for randomized controlled trials as the basis of study evaluation. Studies were done in six different countries.
Findings demonstrate that patient-based educational interventions for cancer pain improve knowledge and attitudes and can reduce pain intensity. The fact that effects were greater in studies with no attentional control raises the question of the benefits of attention itself. Authors observed that benefits were associated with both single- and multiple-exposure studies. Authors pointed out that the weighted mean difference in pain intensity, with educational interventions, was as large as that reported in another analysis for some types of co-analgesic therapies. This finding supports the clinical relevance of providing patient education.
Most of this research was done early in cancer care and may not be directly applicable to patients in later phases of care. Additional research, with long-term follow-up and other patient groups, is needed.
Bennett, M.I., Laird, B., van Litsenburg, C., & Nimour, M. (2013). Pregabalin for the management of neuropathic pain in adults with cancer: A systematic review of the literature. Pain Medicine, 14, 1681–1688.
PHASE OF CARE: Multiple phases of care
APPLICATIONS: Elder care
The studies included one case report, two observational studies, one open-label study, and one double-blinded, four-group, randomized, controlled trial comparing pregabalin, gabapentin, amitriptyline, and a placebo. The most common side effects reported with pregabalin were dizziness, somnolence, headache, fatigue, dry mouth, nausea, ataxia, tremor, peripheral edema, weight gain, blurred vision, and constipation.
This review concluded that the current evidence for the efficacy of pregabalin for cancer-related neuropathic pain is too limited to draw any conclusions.
Pregabalin has been suggested as an approach for the management of chronic, neuropathic, cancer-related pain. However, there is very limited evidence to prove its efficacy.
Bennett, M.I. (2011). Effectiveness of antiepileptic or antidepressant drugs when added to opioids for cancer pain: Systematic review. Palliative Medicine, 25, 553–559.
PHASE OF CARE: Not specified
APPLICATIONS: Palliative care
Six studies examined gabapentin, sodium valproate, or phenytoin, and two studies examined amitriptyline or imipramine. In two randomized, controlled trials, (RCTs) opioid doses were varied according to pain intensity, and in five trials, the opioid doses remained stable. The studies of phenytoin and valproate did not report pain intensities. For gabapentin, two RCTs and two observational studies reported an average benefit of 0.8 points (10-point scale, p = 0.025), but the reports of the percent of patients achieving at least a 30% pain relief were mixed. For amitriptyline, one study reported a benefit of 0.9 points of worst pain (p = 0.035), and one abstract did not report results. For gabapentin, adverse event outcomes were inconsistent; one RCT reported withdrawals caused by the medication, including one death. Respiratory depression was reported in two RCTs. Amitriptyline was associated with increased confusion, dry mouth, and drowsiness. The most common side effects were somnolence and dizziness.
The findings of this analysis suggest that the addition of antiepileptics and antidepressants to opioids for cancer-related neuropathic pain management may result in a small improvement in pain intensity at the risk of more adverse events.
Adjuvant medications in addition to opioids for cancer-related neuropathic pain may be helpful for some patients; however, there is a need for skillful use and follow-up to evaluate the effect of adverse events. In some patients, these adverse events were severe. At the same time, the small changes in pain intensity reported here raise the question of whether these differences are clinically relevant and sufficient to warrant the risk of adverse events. Pain management needs to be highly individualized.
Bennett, S., Pigott, A., Beller, E.M., Haines, T., Meredith, P., & Delaney, C. (2016). Educational interventions for the management of cancer-related fatigue in adults. Cochrane Database of Systematic Reviews, 11, CD008144.
STUDY PURPOSE: To evaluate the effectiveness of educational interventions for managing fatigue in adults with cancer
TYPE OF STUDY: Meta-analysis and systematic review
PHASE OF CARE: Multiple phases of care
Educational interventions appear to play some role in reducing overall fatigue, fatigue intensity, and fatigue interference, and might provide some benefit for anxiety. No effect on depression was found in this study, but baseline levels of depression were not generally clinically relevant.
The incorporation of educational interventions as part of care to manage fatigue is reasonable but may not be sufficient to have a clinically meaningful impact.
Bennett-Guerrero, E., Pappas, T.N., Koltun, W.A., Fleshman, J.W., Lin, M., Garg, J., . . . SWIPE 2 Trial Group. (2010). Gentamicin-collagen sponge for infection prophylaxis in colorectal surgery. New England Journal of Medicine, 363, 1038–1049.
The purpose of the study was to determine if an implantable gentamicin-collagen sponge prevents surgical infections in patients undergoing colorectal surgery.
Patients undergoing laparoscopic colorectal surgery in one of the 39 sites participating in the trial were randomized into either the sponge group or the control group after the surgical incision was made. If randomized into the experimental group, patients had a sponge (10 x 10 cm) implanted internally along their incision line just prior to the surgeon closing the wound that contained 280 mg of collagen and 130 mg of gentamicin. Both groups received standard of care of antibiotics 60 minutes prior to incision. Individuals who analyzed results were blinded to patient assignment.
Multiple sites
Multiple phases of care
Phase III blinded randomized, controlled trial
Surgical infections occurred more frequently in the sponge group with a rate of 30% as compared to the control group at 20%. Superficial site infections also were higher in the sponge group than the control group. The sponge group also was more likely to visit the emergency department or physician offices with wound-related complications (19% versus 11%).
The gentamicin collagen sponge is not effective in preventing surgical site infections in patient undergoing colorectal surgery.
The study did not determine if the sponge could be used to treat infection but, instead, focused only on infection prevention.
The gentamicin collagen sponge is not only not effective in preventing infection, but based on this study, may increase a patient’s risk for surgical wound infection.
Ben-David, M.A., Elkayam, R., Gelernter, I., & Pfeffer, R.M. (2016). Melatonin for prevention of breast radiation dermatitis: A phase II, prospective, double-blind randomized trial. The Israel Medical Association Journal, 18, 188–192. Retrieved from https://www.ima.org.il/filesupload/imaj/0/193/96915.pdf
To evaluate a cream containing melatonin in terms of efficacy in reducing acute radiation dermatitis during and immediately after radiation therapy, and to examine patient-reported comfort during the study period
PHASE OF CARE: Active antitumor treatment
Phase II, prospective, double-blind, randomized
The researchers reported no significant difference in skin toxicity for both groups for the first four weeks of radiation treatment. The authors reported findings of significance in terms of reduced radiation dermatitis in the melatonin group at week five to seven (p = 0.049). After radiation was complete, the authors reported significant findings at the two-week follow-up visit in terms of reduced dermatitis in the melatonin group (p = 0.03). The researchers found no difference in the melatonin group and placebo group patient questionnaire reports of symptoms during treatment (including pain, burning, itching). Other analysis showed that women in the melatonin group who were older and smoked showed less radiation dermatitis (significance values p = 0.021 and p = 0.007). Four patients in the melatonin group sustained an allergic reaction limited to the treated skin, which required treatment with a topical and/or oral steroid.
Women with early stage breast cancer (stage 0–II) who are status postlumpectomy and undergoing daily radiation treatment for five weeks may experience reduced skin toxicity from the twice daily application of a melatonin containing cream to the treatment area.
As there is currently no consensus or evidence-based practice to follow for the treatment for radiation dermatitis, this study could be used to identify a treatment option and possibly specific product use in other institutions where radiation is delivered. Although this study was limited to women with breast cancer who had undergone lumpectomy, there could be utility in applying the melatonin cream to patients undergoing radiation therapy for other types of cancers (e.g., head and neck cancer).
Ben-Aharon, I., Gafter-Gvili, A., Paul, M., Leibovici, L., & Stemmer, S.M. (2008). Interventions for alleviating cancer-related dyspnea: A systematic review. Journal of Clinical Oncology, 26(14), 2396-2404.
The objective of this study was to systematically review the evidence for the efficacy of pharmacologic and nonpharmacologic treatments in alleviating dyspnea in patients with terminal cancer.
Databases searched were Cochrane Library up to 2007, MEDLINE (PubMed) (1966–2007), American Society of Clinical Oncology conference proceedings, and references of all included documents. In addition to databases, the search included the reference lists of key studies, the reference lists of 16 review articles on the topic, reference lists from 16 textbooks, and seven websites. Authors (15) of main investigations were contacted, and all members of the Association of Palliative Care and users of the www.palliativedrugs.com bulletin board were contacted for additional information and unpublished data.
Search keywords were opiate, opioid, morphine, benzodiazepine, furosemide, steroids, corticosteroids, oxygen, nonpharmacological, acupuncture, nursing, cancer, carcinoma, malignancy, dyspnea and breathlessness.
Studies were included in the review if they were a randomized controlled trial assessing dyspnea in patients with terminal cancer in which any intervention for dyspnea relief was compared with no intervention, placebo, or another intervention.
Studies were excluded if they were nonrandomized studies or trials in which only a minority of the patients had a cancer diagnosis.
Literature evaluated included 37 studies, plus one abstract initially reviewed. A final set of 18 studies was included; 7 assessed opioids, 6 assessed oxygen- or helium-enriched air, 1 assessed furosemide, and 4 assessed nonpharmacologic interventions. Meta-analysis was not completed due to the paucity of studies and heterogeneous outcome measures.
Sample Size Across Studies:
Sample Range Across Studies:
With respect to gender, age, and diagnosis within the sample, the opioids subgroup included both genders. The median age range was 56–73 years. The majority had primary lung cancer, and both opioid-tolerant and opioid-naïve participants were included.
The oxygen or helium subgroup included both genders. The median age range was 64–72 years. The majority had primary lung cancer.
No comment was available on gender or age for the nonpharmacologic subgroup, but the primary diagnosis was lung cancer.
The primary outcome was subjective dyspnea relief according to the visual analog scale (VAS) or dyspnea intensity according to the modified Borg scale. The secondary outcome was oxygen saturation and adverse effects.
Opioid Intervention:
Oxygen Intervention:
Furosemide Intervention:
Nonpharmacologic Interventions:
Acknowledging the paucity of evidence from randomized controlled trials to support the interventions is important.
Limitations of this review were
A major research opportunity exists to further document outcomes from nurse-led dyspnea interventions.
Ben-Aharon, I., Gafter-Gvili, A., Leibovici, L., & Stemmer, S.M. (2012). Interventions for alleviating cancer-related dyspnea: A systematic review and meta-analysis. Acta Oncologica (Stockholm, Sweden), 51, 996-1008.
The objective of this meta-analysis and systematic review was to evaluate the role of different interventions to alleviate dyspnea.
A total of 829 references were retrieved. The specific method of evaluation was not described, but the small sample size of most studies was noted.
Patients were undergoing end-of-life care.
Findings provide guidance regarding effectiveness of interventions for dyspnea in patients with cancer. These results demonstrate the effectiveness of opioids. Findings also confirm those of others that palliative oxygen is of no benefit for this symptom. Some reviews continue to suggest the use of palliative oxygen. This is not supported by evidence, and home oxygen therapy is generally not covered by insurance for patients who do not have hypoxemia. Unnecessary use can be costly to the patient. Evidence is limited regarding the effects of the addition of hypnotics to opioids in managing dyspnea. This is an area that could benefit from additional research.
Belmonte, R., Tejero, M., Ferrer, M., Muniesa, J.M., Duarte, E., Cunillera, O., & Escalada, F. (2011). Efficacy of low-frequency low-intensity electrotherapy in the treatment of breast cancer-related lymphoedema: A cross-over randomized trial. Clinical Rehabilitation, 26(7), 607–618.
To compare efficacy of low-frequency, low-intensity electrotherapy and manual lymphatic drainage in treatment of upper-limb lymphedema
Patients were randomized to two groups. Group A underwent electrotherapy therapy for 10 sessions followed by 10 sessions of manual drainage. Group B underwent manual drainage first and then received electrotherapy. There was a month washout period between treatments. Patients were assessed after every 10 treatment sessions. Electrotherapy was delivered with a system that provides massage with low-frequency electrical stimulation.
The study took place in an outpatient setting in Spain.
The study has clinical applicability for late effects and survivorship.
The study used a randomized crossover trial design.
There were no significant differences in outcomes between the two treatments.
There was no difference in benefits from manual lymphatic drainage and low-frequency, low-intensity electrotherapy.
Findings suggest there is no difference in efficacy of these two treatment approaches for management of arm lymphedema in patients with breast cancer.